t
| Date | 28 Feb 2023 |
| Time | 17:45:59 |
| Category | Capital structure |
| ID | 4049R |
28 February 2023
Aptamer Group plc
("Aptamer", the "Company" or the "Group")
Block Listing Interim Review
Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, makes the following notification pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies regarding its existing block admission:
|
Name of Company |
Aptamer Group plc |
|
Name of Scheme |
The Aptamer Group EMI Share Option Scheme |
|
Period of Return (from/to) |
25 August 2022 to 24 February 2023 |
|
Number and class of securities not issued at the start of the period under the scheme |
1,792,400 Ordinary Shares |
|
Number of securities issued under the scheme during the period |
34,123 |
|
Options waived and not to be exercised |
91,800 |
|
Balance under the scheme of securities not yet issued at the end of the period |
1,666,477 |
|
Number and class of securities originally admitted and the date of admission |
2,063,200 Ordinary Shares on 25 February 2022 |
|
Name of contact and telephone number |
Jenny Cutler +44 (0) 1904 217 404 |
- ENDS -
For further information, please contact:
|
Aptamer Group plc |
+44 (0) 1904 217 404 |
|
Dr Arron Tolley - CEO |
|
|
|
|
|
SPARK Advisory Partners Limited - Nominated Adviser |
+44 (0) 20 3368 3550 |
|
Andrew Emmott / Mark Brady / Adam Dawes |
|
|
|
|
|
Liberum Capital Limited - Broker |
+44 (0) 20 3100 2000 |
|
Richard Lindley / Ben Cryer / Cara Murphy |
|
|
|
|
|
Consilium Strategic Communications |
+44 (0) 20 3709 5700 |
|
Matthew Neal / Chris Welsh / Lucy Featherstone |
|
About Aptamer Group plc
Aptamer Group develops custom affinity binders through its proprietary Optimer® platform to enable new approaches in therapeutics, diagnostics and research applications. The Company strives to deliver transformational solutions that meet the needs of life science researchers and developers through the use of its proprietary Optimer platform.
Optimer binders are oligonucleotide affinity ligands that can function as an antibody alternative. The global antibody market is currently worth over $145bn. Optimer binders are engineered to address many of the issues found with alternative affinity molecules, such as antibodies, and offer new, innovative solutions to bioprocessing, diagnostic and pharmaceutical scientists.
Aptamer Group has successfully delivered projects for global pharma companies, diagnostic development companies, and research institutes covering a range of targets and applications with the objective of establishing royalty-bearing licenses. Through the unique Optimer technology and processes, scientists and collaborators are enabled to make faster, more informed decisions that support discovery and development across the Life Sciences.